bimatoprost, Latisse, Lumigan

  • Pharmacy Author:
    Omudhome Ogbru, PharmD

    Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

  • Medical and Pharmacy Editor: William C. Shiel Jr., MD, FACP, FACR
    William C. Shiel Jr., MD, FACP, FACR

    William C. Shiel Jr., MD, FACP, FACR

    Dr. Shiel received a Bachelor of Science degree with honors from the University of Notre Dame. There he was involved in research in radiation biology and received the Huisking Scholarship. After graduating from St. Louis University School of Medicine, he completed his Internal Medicine residency and Rheumatology fellowship at the University of California, Irvine. He is board-certified in Internal Medicine and Rheumatology.

View the Eye Diseases and Conditions Slideshow Pictures

GENERIC NAME: bimatoprost

BRAND NAME: Latisse, Lumigan

DRUG CLASS AND MECHANISM: Bimatoprost is a synthetic (man-made) drug that resembles and mimics the effects of natural chemicals (prostaglandins) produced by the body and is used for reducing intraocular pressure (IOP) and increasing the growth of eyelashes. The exact mechanism of action is unknown. Bimatoprost may reduce IOP by increasing the outflow of aqueous humor from the eye of individuals with narrow angle glaucoma. Excessive aqueous humor may cause optic nerve damage and visual loss. It may increase eyelash growth by increasing the duration of the growing phase of the eyelash.

The FDA approved Lumigan in March 2001 and Latisse in December 2008.

PRESCRIBED FOR: Bimatoprost is used for reducing IOP in individuals with narrow angle glaucoma or ocular hypertension. It also is used for increasing thickness, length, and darkness of eyelashes.

SIDE EFFECTS: Common side effects include:

  • Itching of the eyes
  • Growth of eyelashes
  • Eye irritation
  • Dry eyes
  • Eye redness
  • Eye lash darkening and reversible darkening of skin around the eyes

Bimatoprost may also cause permanent brown pigmentation in the colored part of the eye and hair growth in other areas of the body that it comes in contact with.

PRESCRIPTION: Yes

GENERIC AVAILABLE: No

PREPARATIONS: Solution (eye drops): 0.01% and 0.03%

STORAGE: S Solutions should be store at 2 C to 25 C (36 F to 77 F).

DOSING: The recommended dosage of bimatoprost for reducing IOP is one drop of Lumigan 0.01 or 0.03% in the affected eye(s) once daily in the evening. More frequent administration may reduce the IOP-reducing effect. Reduction in IOP starts approximately four hours after administration and maximum effect occurs in approximately 8 to 12 hours.

Medically Reviewed by a Doctor on 12/17/2014
Eye Conditions Quiz: Test Your IQ
FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

See more info: bimatoprost on RxList
RxList Logo

Need help identifying pills and medications?

Use the pill identifier tool on RxList.

Subscribe to MedicineNet's Newsletters

Get the latest health and medical information delivered direct to your inbox!

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Health Solutions From Our Sponsors